论文部分内容阅读
目的 :评价玻璃体切割术治疗视网膜静脉周围炎伴玻璃体出血的疗效。方法 :回顾性分析我院自 1999年 3月至2 0 0 2年 9月经玻璃体切割术治疗的视网膜静脉周围炎伴玻璃体出血患者 13例 18只眼的临床资料。结果 :随访期为 7个月～ 4年 ,平均 2 3个月。 18只眼视网膜均在位 ,16只眼 (88 9% )视力较术前有不同程度的提高 ,其中视力≥ 0 3者 11只眼(71% ) ,最好视力为 1 0。术后玻璃体再出血 2例 ,经药物治疗后出血吸收。无新生血管性青光眼发生。结论 :玻璃体切割术是治疗视网膜静脉周围炎伴玻璃体出血的有效方法 ,可明显改善患者视力 ;结合术中及术后激光光凝治疗 ,可有效预防玻璃体再出血及新生血管性青光眼等并发症的发生
OBJECTIVE: To evaluate the efficacy of vitrectomy in the treatment of retinal vein inflammation with vitreous hemorrhage. Methods: The clinical data of 13 eyes of 13 patients with PVR accompanied by vitreous hemorrhage treated by vitrectomy in our hospital from March 1999 to September 2002 were retrospectively analyzed. Results: The follow-up period ranged from 7 months to 4 years with an average of 23 months. The retina of all 18 eyes was in place, and the visual acuity of 16 eyes (88.9%) was improved to some extent compared with the preoperative level. Among them, 11 eyes (71%) had visual acuity ≥ 0.3, and the best visual acuity was 10. Postoperative vitreous hemorrhage in 2 cases, the bleeding after absorption of the drug treatment. No neovascular glaucoma occurs. Conclusion: Vitrectomy is an effective method for the treatment of retinal vein inflammation accompanied by vitreous hemorrhage, which can significantly improve the visual acuity of patients. Combined with intraoperative and postoperative laser photocoagulation, it is effective in preventing the complications of vitreous hemorrhage and neovascular glaucoma occur